| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.5 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |